repaglinide and metformin combination tablet — Competitive Intelligence Brief

repaglinide and metformin combination tablet (repaglinide and metformin combination tablet) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor and biguanide. Area: Diabetes.

phase 3 DPP-4 inhibitor and biguanide Diabetes Small molecule

Target snapshot

repaglinide and metformin combination tablet (repaglinide and metformin combination tablet) — Novo Nordisk A/S. Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
repaglinide and metformin combination tablet TARGET	repaglinide and metformin combination tablet	Novo Nordisk A/S	phase 3	DPP-4 inhibitor and biguanide
CSII followed by Lina+MET	CSII followed by Lina+MET	Sun Yat-sen University	marketed	Insulin therapy combined with DPP-4 inhibitor and biguanide	Insulin receptor (CSII); DPP-4 enzyme (linagliptin); mitochondrial glycerophosphate dehydrogenase (metformin)
Sitagliptin plus metformin	Sitagliptin plus metformin	Merck Sharp & Dohme LLC	phase 3	DPP-4 inhibitor and biguanide	DPP-4
Matching Placebo to Sita/Met FDC	Matching Placebo to Sita/Met FDC	Merck Sharp & Dohme LLC	phase 3	DPP-4 inhibitor and biguanide combination	DPP-4
Placebo to sitagliptin plus metformin	Placebo to sitagliptin plus metformin	Merck Sharp & Dohme LLC	phase 3	DPP-4 inhibitor and biguanide	DPP-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor and biguanide class)

1. Merck Sharp & Dohme LLC · 2 drugs in this class
2. Novo Nordisk A/S · 1 drug in this class